1. Home
  2. VYGR vs CPSS Comparison

VYGR vs CPSS Comparison

Compare VYGR & CPSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • CPSS
  • Stock Information
  • Founded
  • VYGR 2013
  • CPSS 1991
  • Country
  • VYGR United States
  • CPSS United States
  • Employees
  • VYGR N/A
  • CPSS 925
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • CPSS Finance: Consumer Services
  • Sector
  • VYGR Health Care
  • CPSS Finance
  • Exchange
  • VYGR Nasdaq
  • CPSS Nasdaq
  • Market Cap
  • VYGR 235.4M
  • CPSS 225.2M
  • IPO Year
  • VYGR 2015
  • CPSS 1992
  • Fundamental
  • Price
  • VYGR $4.22
  • CPSS $10.52
  • Analyst Decision
  • VYGR Strong Buy
  • CPSS
  • Analyst Count
  • VYGR 9
  • CPSS 0
  • Target Price
  • VYGR $15.53
  • CPSS N/A
  • AVG Volume (30 Days)
  • VYGR 374.5K
  • CPSS 28.8K
  • Earning Date
  • VYGR 03-03-2025
  • CPSS 03-14-2025
  • Dividend Yield
  • VYGR N/A
  • CPSS N/A
  • EPS Growth
  • VYGR N/A
  • CPSS N/A
  • EPS
  • VYGR 0.47
  • CPSS 0.87
  • Revenue
  • VYGR $163,784,000.00
  • CPSS $184,246,000.00
  • Revenue This Year
  • VYGR N/A
  • CPSS N/A
  • Revenue Next Year
  • VYGR N/A
  • CPSS $17.21
  • P/E Ratio
  • VYGR $9.13
  • CPSS $12.61
  • Revenue Growth
  • VYGR 3.40
  • CPSS N/A
  • 52 Week Low
  • VYGR $4.00
  • CPSS $7.03
  • 52 Week High
  • VYGR $10.66
  • CPSS $12.73
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 29.98
  • CPSS 38.44
  • Support Level
  • VYGR $4.20
  • CPSS $10.70
  • Resistance Level
  • VYGR $4.60
  • CPSS $11.67
  • Average True Range (ATR)
  • VYGR 0.31
  • CPSS 0.47
  • MACD
  • VYGR -0.08
  • CPSS -0.08
  • Stochastic Oscillator
  • VYGR 12.36
  • CPSS 0.00

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About CPSS Consumer Portfolio Services Inc.

Consumer Portfolio Services Inc is a U.S.-based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent, by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.

Share on Social Networks: